Amol Akhade, Senior Consultant at Fortis Hospitals Mumbai, shared a post on X:
“Keynote B15. Nice curves for Efs and Os. Question is:
How Many got nivolumab on progression in Gem Cis arm and what was their outcome? anyone has that data?
Cross trial comparison and where we are heading in MIBC.
Will EV work after DV? This question is going to come again and again in MIBC trials in future.
CtDNA has entered MIBC space. Prognostic for sure. Predictive?
The PSA relapse and OS Paradox. Nice to see this being discussed.
Other articles about ASCO on OncoDaily.
